|
|
Substance Name: Ribociclib succinate [USAN]
RN: 1374639-75-4
UNII: BG7HLX2919
InChIKey: NHANOMFABJQAAH-UHFFFAOYSA-N
Note
- Inhibits both CDK4 and CDK6
NCI: An orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. CDK4/6 inhibitor LEE011 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation. (NCI Thesaurus)
Molecular Formula
- C23-H30-N8-O.C4-H6-O4
Molecular Weight
- 552.6324
Classification Code
- Antineoplastic
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Name of Substance
- Ribociclib succinate
- Ribociclib succinate [USAN]
Synonyms
- Butanedioic acid, compd. with 7-cyclopentyl-N,N-dimethyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-7H-pyrrolo(2,3-d)pyrimidine-6-carboxamide (1:1)
- Kisqali
- LEE-011 succinate
- LEE011-BBA
- Ribociclib succinate
- UNII-BG7HLX2919
Registry Numbers
CAS Registry Number
- 1374639-75-4
FDA UNII
- BG7HLX2919
System Generated Number
- 1374639754